PharmaMar Presents New Data on Plitidepsin, Lurbinectedin Therapies to Treat Ovarian Cancer, Multiple Myeloma

PharmaMar Presents New Data on Plitidepsin, Lurbinectedin Therapies to Treat Ovarian Cancer, Multiple Myeloma
Plitidepsin and lurbinectedin, two drugs advancing in clinical studies for the treatment of ovarian cancer and other malignancies, were the focus of two PharmaMar presentations at the April 1-5 American Association of Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. The first presentation, “Plitidepsin targets the moonlighting functions of eEF1A2 in cancer,” revealed the exact mechanism of action of plitidepsin, a drug originally obtained from the sea squirt Aplidium albicans that binds to the eukaryotic elongation factor 1A2 (eEF1A2). The protein eEF1A2 has been found to be expressed in many tumors, including ovarian cancer and multiple myeloma. Plitidepsin was assessed in the recently finished pivotal ADMYRE Phase 3 trial (NCT01102426) for the treatment of multiple myeloma. The study enrolled 255 U.S., European and Asian patients with relapsed and refractory multiple myeloma and who had received at least three but no more than six prior treatment regimens. Patients were randomized to receive either plitidepsin plus dexamethasone or dexamethasone alone. The combo therapy reduced the risk of disease progression or death by 35 percent compared to dexamethsone alone. Based on the findings, Spain's PharmaMar applied to the 
Subscribe or to access all post and page content.